Wieslaw Bal

Maria Sklodowska Curie National Research Institute Of Oncology Gliwice Branch
Gliwice, SL 44101, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Correction: Melanoma genomics- will we go beyond BRAF in clinics?

Correction: Melanoma genomics- will we go beyond BRAF in clinics?

Journal: Journal of cancer research and clinical oncology

Published: February 13, 2025

Chemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitors.

Chemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitors.

Journal: Contemporary oncology (Poznan, Poland)

Published: February 04, 2025

Melanoma genomics - will we go beyond BRAF in clinics?

Melanoma genomics - will we go beyond BRAF in clinics?

Journal: Journal of cancer research and clinical oncology

Published: July 26, 2024

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report.

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report.

Journal: Cancers

Published: July 05, 2023

Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.

Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.

Journal: Melanoma research

Published: April 04, 2023

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.

Journal: Targeted oncology

Published: February 19, 2023

Characteristics of Giant Nodular Melanomas in Special Locations: a Case Series and Review of the Literature.

Characteristics of Giant Nodular Melanomas in Special Locations: a Case Series and Review of the Literature.

Journal: Dermatology and therapy

Published: September 05, 2022

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.

Journal: Cancers

Published: April 02, 2022

Relevance of admission hyperglycaemia and diabetes mellitus to efficacy and safety of mechanical thrombectomy in stroke patients.

Relevance of admission hyperglycaemia and diabetes mellitus to efficacy and safety of mechanical thrombectomy in stroke patients.

Journal: Neurologia i neurochirurgia polska

Published: March 27, 2022

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.

Journal: Journal of clinical medicine

Published: March 23, 2022

Clinical and Non-Clinical Determinants of the Effect of Mechanical Thrombectomy and Post-Stroke Functional Status of Patients in Short and Long-Term Follow-Up.

Clinical and Non-Clinical Determinants of the Effect of Mechanical Thrombectomy and Post-Stroke Functional Status of Patients in Short and Long-Term Follow-Up.

Journal: Journal of clinical medicine

Published: August 29, 2021

NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.

NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.

Journal: Genes

Published: May 31, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026